The serum opacity reaction of Streptococcus pyogenes (Group A streptococci), first described by Ward and Rudd (1), is associated with a lipoproteinase which acts upon the ax-lipoprotein fraction of serum to produce a measurable opalescence (2-4). Evidence of the antigenicity of streptococcal lipoproteinase in rabbits and in humans has been presented both by Krumwiede and by Rowen (2, 5). Krumwiede found that sera of rabbits immunized with filtrates of an enzyme-producing strain grown in rabbit serum inhibited the serum opacity reaction (SOR) produced by that strain. Moreover, the addition of certain human sera or a sample of human -y-globulln to horse serum-enzyme mixtures was found to prevent the splitting of serum lipoprotein by streptococcal lipoproteinase. Rowen demonstrated a substance capable of inhibiting the opalescence produced by fipoproteinase in the sera of 25-30 % of adults tested, and suggested that this inhibitory substance might be antibody.
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The serum opacity reaction of Streptococcus pyogenes (Group A streptococci), first described by Ward and Rudd (1) , is associated with a lipoproteinase which acts upon the ax-lipoprotein fraction of serum to produce a measurable opalescence (2) (3) (4) . Evidence of the antigenicity of streptococcal lipoproteinase in rabbits and in humans has been presented both by Krumwiede and by Rowen (2, 5) . Krumwiede found that sera of rabbits immunized with filtrates of an enzyme-producing strain grown in rabbit serum inhibited the serum opacity reaction (SOR) produced by that strain. Moreover, the addition of certain human sera or a sample of human -y-globulln to horse serum-enzyme mixtures was found to prevent the splitting of serum lipoprotein by streptococcal lipoproteinase. Rowen demonstrated a substance capable of inhibiting the opalescence produced by fipoproteinase in the sera of 25-30 % of adults tested, and suggested that this inhibitory substance might be antibody.
Studies by Gooder (6) , by K6hier (7), and from this laboratory (8) indicate a high degree of association between lipoproteinase production and certain serotypes of Group A streptococci. Furthermore, strains of Group A streptococci which are difficult to type by the M-precipitin method are often good producers of lipoproteinase (6) (7) (8) An antigen of Group A streptococci exhibiting a close association with certain serotypes and produced by strains which are difficult to characterize pre-cisely by currently available methods might provide distinct advantages in the identification of streptococcal strains. Further investigations into the antigenicity of streptococcal lipoproteinase thus seemed warranted. Such investigations are described in this paper, which demonstrates the existence of many antigenically distinct streptococcal lipoproteinases, each of which shows remarkable specificity for a certain group of strains.
Methods
Group A Streptococcal Strains Used.--All strains used in these experiments were examined for group, M type, T-agglutination pattern, and (when indicated) the 28 R antigen by standard techniques (9, 10, 16) .
The following arbitrarily arranged groups of strains were tested with the various SOR inhibitory antisera produced: Preparation of Vaccines.--Lipoproteinase-producing strains were inoculated into 1.6 liters of Todd-Hewitt broth and incubated at 37°C for 16-18 hr. The cells were collected by eentrifugation, washed three times in 0.9% saline, and resuspended in 25 ml saline. 3 ml of 1% merthiolate were added to the suspension. After disruption in a Midde disintegrator, the fraction containing ceil walls and membranes was coilected by centrifugation at 20,000 g. The cell wall-membrane fraction was washed twice in saline and resuspended in 100 ml saline. This suspension was plated to assure absence of viable streptococci and was then used as a vaccine. 0.2 ml of vaccine was incubated overnight at 37"C in 1.0 ml horse serum to make certain that the vaccine contained active enzyme.
Immunisation.--Albino rabbits were immunized intravenously with the vaccine according to the following schedule: 5 days after an initial intravenous injection of 0.5 ral of vaccine, the rabbit was reinjected on 3 consecutive days and then rested for 4 clays before the next series of three injections. After the first four injections of 0.5 ml, the dosage was increased to 1.0 ml of vaccine if tolerated by the animal. After 15-18 total injections, rabbits were rested for 5 days and bled. Their serum was tested for ability to inhibit the SOR of the vaccine strain. If inhibitory activity was demonstrated, the rabbit received 1.0 ml injections of vaccine each week and was bled weekly as long as acceptable antiserum was produced. If serum-neutralizing capacity was low or not present at the first postimmunization bleeding, the rabbit was continued on thrice weekly injections for an additional 4 wk, at which time its serum was retested for inhibitory antibodies. Preimmunization serum was obtained from most rabbits and tested for inhibition of the serum opacity reaction of the immunizing strain.
Preparation of Enzyme for Serum Opacity Inhibition
Tests.--Either merthiolate-treated cells or desoxychoiate extracts of a streptococcal cell wall and membrane fraction were satisfactory as a source of enzyme for serum opacity inhibition tests. To prepare cells, a strain was inoculated into 25 ml Todd-Hewitt broth which was incubated at 37°C for 16-18 hr. 1 ml of 1% merthiolate solution was added to the overnight broth culture. The cells were harvested by centrifugation, washed twice in saline, and thoroughly suspended in 5 ml of 0.9% saline. After the addition of two drops of 1% merthiolate, the cells were stored at 4°C. No loss of activity was noted after storage for 7 days at 4°C. To prepare soluble desexycbolate extracts (4), an overnight growth of cells at 37°C in 200 ml Todd-Hewitt broth was collected by centrifugation, washed three times in 0.9% saline, and resuspended in 7 ml of saline. After complete disruption of the cells in a Mickle disintegrator, the cell wail-membrane fraction was collected by centrifugation at 20,000 g and washed twice in 0.9% saline. The ceil wall-membrane fraction was thoroughly suspended in 2--4 ml of a 1% sodium desoxycholate solution and incubated overnight at 4°C. A clear supematant fluid containing activity was obtained after centrifugation at 20,000 g. No appreciable loss of activity was evident after storage of this A tD f,. of each tube was measured at a wave length of 475 m# in a Coleman Junior Spectrophotometer using optically matched 10 X 100 mm glass tubes. The supernatant of tube II was used as a blank for the supernatant of tube I, and the difference in optical density (AODas) between these tubes represents the serum opacity produced by the amount of enzyme incubated in the system containing nonimmune serum. The supernatant of tube IV was used as a blank for the supernatant of tube HI and the AOD4~5 of these tubes represents the serum opacity produced by the same amount of enzyme as in tube I after preincubation with immune serum. The difference between the AOD475 of tubes I and II and the AOD4~ of tubes HI and IV represents the amount of serum opacity inhibition by the immune serum. Fig. 1 shows the serum opacity produced by various comparable amounts of cell suspensions from several different strains of Group A streptococci. Stock cell suspensions of six different strains were adjusted to a AOD~00 of 0.20. Twofold dilutions were made of these adjusted stock suspensions and a 0.2 ml aliquot was incubated in a system with 0.2 ml of nonimmune rabbit serum and 1.0 ml horse serum for 16 hr at 37°C. The serum opacity produced by comparable dilutions of ceils from these strains is plotted on the ordinate. A straight line relationship between amount of cells added and the serum opacity produced is apparent up to a AOD475 of 0.15. Above 0.15, the AOD476 is no longer directly proportional to the amount of cells added. This phenomenon was found to hold both for cell suspensions and for desoxycholate extracts of the many serotypes tested and probably represents substrate limitation in the system. Consequently for tests of serum opacity inhibition, a predetermined dilution which would give a AOD475 after preincubation in nonimmune serum of 0.06--0.15 was used. To eliminate the effects of varying amounts of substrate in different lots of horse sera, one lot of serum was used for a series of experiments.
Immune antiserum was used with experiments only if it was sufficiently potent to inhibit the amount of enzyme of the immunizing strain which produced a AOD47u of 0.10 after preincubation in nonimmune serum to a AOD4~5 of less than 0.02 after preincubation in antiserum. Antisera of this potency permitted a clear distinction between inhibition and lack of inhibition and were felt to be of sufficient strength to permit detection of partial inhibition of the serum opacity reaction, if such occurred.
RESULTS
The method of measuring the serum opacity reaction (SOR) and inhibition of the reaction, as described above, has been found to be quite reproducible. When equivalent dilutions of enzyme of the same strain were used in a series of duplicate determinations, rarely did the AOD475 vary by more than 4-0.02. One variable in the system which cannot be readily eliminated is the rabbit serum itself. The rabbit serum serves not only as a source of antibody but also as a source of substrate (arlipoprotein) and therefore contributes to the opalescence which develops after incubation with streptococcal lipoproteinase. Variations in the al-lipoprotein content of the noDimmune and immune rabbit sera used can thus result in differences in the AOD,76 produced by the enzyme in each serum. Sera were occasionally encountered which produced an increase or decrease in nOD476 of greater than 0.02 (up to 0.04) when compared with values obtained with a standard noDimmtme reference rabbit serum. Exclusion of such sera from the following experiments eliminated variations in substrate concentration of rabbit serum as a cause of significant variation in the opacity produced.
Inhibitory activity to the lipoproteinase produced by several strains of different antigenic composition was not encountered in the sera of over 25 unimmunized rabbits tested. Prelmmunization sera obtained from rabbits which later developed inhibitory antibodies to the lipoproteinase of the immunizing strain invariably contained no inhibitory activity to this strain.
Since preliminary experiments suggested the possibility of multiple streptococcal lipoproteinases with a high degree of strain specificity, antisera to preparations from 12 different lipoproteinase-producing strains of various T-agglutination patterns were examined in detail for their capacity to inhibit the serum opacity reaction of strains of homologous and of heterologous antigenic compositions with respect to their T, M, and R antigens.
T-Agglutination Pattern~ Associated witk One Antigenically Distinct Lipoproteinase

Strains of T-Agglutination Pattern 2.--
A vaccine made from a prototype strain (T2/44/Rb4/91/1) of T-agglutination pattern 2 produced suitable antiserum in all three rabbits immunlz~:i. A representative group of determinations of the influence of this immune rabbit serum on the serum opacity reaction produced by desoxycholate extracts of several homotypic and heterotypic strains is shown in Table II . It is evident that the serum opacity reaction produced by the three strains of T pattern 2 is completely inhibited after preincubation with the type 2 antiserum while the serum opacity reaction of strains of other T patterns is not inhibited by this antiserum. The effects of this type 2 antiserum on a larger group of strains of various antigenic compositions and from various sources are summarized in Table HI . The SOR of all strains of T-agglutination pattern 2 was inhibited by the antiserum irrespective of their production or lack of production of the type 2 M antigen or of the 28 R antigen as determined by precipitin tests. The serum opacity reaction of all 69 strains of heterologous T-agglutination patterns was not inhibited by the type 2 SOR antisera. The serum opacity reaction of four representative T-2 strains, whose SOR was inhibited by type 2 antisera, was not inhibited by the heterologous SOR-inhibitory antisera subsequently described. (One of the 12 antisera, CV238 antiserum, was obtained in sufficient quantity to permit the testing of all prototype strains used for immunization but not all other representative strains of heterologous types.) Strains of T Agglutination Pattern 9.--A vaccine prepared from a type 9 strain (Colindale 8316) produced suitable antisera in all three rabbits immunized. The results of S0R inhibition by these antisera are presented in Table IV . The type 9 antisera inhibited the serum opacity reaction of all five strains of T pattern 9, regardless of the presence or absence of M antigen, but did not inhibit the SOR of 45 heterologous strains. The sermn opacity reaction of the 5 strains whose SOR was inhibited by the type 9 antisera was not inhibited by type 2 SOR-inhibitory antisera or by the other SOR-inhlbitory antisera to be described. M-negative, T 11 strains: From Minneapolis, strain 6014, from Red Lake, strain RL583. ~t Neg, negative for 28 R.
Non-M-Typable Strains of T Pattern 12.-
Only non-M-typable strains of T pattern 12 produce a SOR; M-typable type 12 strains have not, in our experience, produced this reaction (8) . A vaccine prepared from a nontypable strain of T pattern 12 (RL3124) produced suitable antiserum in one of the three rabbits immunized. The results of SOP. inhibition by this antiserum are shown in Table V . The SOP. of all six non-M-typable strains of T pattern 12 was inhibited by this antiserum which failed to inhibit the SOR of 67 strains of heterologous serotypes. The SOP. of five of these T-12 strains was examined for inhibition by SOR-inhibitory antisera prepared against heterologous types. The activity of these strains was not inhibited when tested with SOR-inhibitory antisera to types 2 and 9 nor with the other antisera subsequently described.
Strains of T-Agglutination Pattern 14.-
The T pattern 14 is more complex than the three T patterns previously considered in that more than one M type is associated with T antigen 14. M types 14, 35, 49, and 51 are included in this T pattern (11, 12) , although recent studies have suggested that types 35 and 49 are identical (13). Strains of M types 14 and 51 have not been found to produce a serum opacity reaction (8) . HeY~ologous T serotype~: All heterologous strains of groups I, II, and HI (See Methods) plus M-negative, T 3/13/B3264 strain CV392 from Red Lake.
A vaccine made from the prototype type 49 strain (B737/71/1) with T antigen 14 produced suitable antiserum in all rabbits immunized. Results of SOR inhibition with this antiserum are shown in Table VI. All SOR-positive strains of T pattern 14 showed SOR inhibition with B737/71/1 antiserum; these included 13 type 49 strains and two type 35 strains (typed in the laboratory of Dr. Rebecca Lancefield), as well as 18 strains of this T pattern which could not be typed by type 49 M antiserum in our laboratory but which reacted with a specially absorbed 49 T-agglutination serum when examined in our laboratory or by W. R. Maxted (12) . The SOR of three strains, originally SEI~U~ OPACITY REACTION" OF STREPTOCOCCUS PYOGENES classified as M type 49 but of a T pattern (5/27/44) different from the prototype 49 strain, was not inhibited by B737/71/1 antiserum, and no SOR inhibition was found with this antisermn with strains of T pattern other than T-14. In further confirmation of their serologic specificity, the serum opacity reactivities of five strains which had shown SOR inhibition with B737/71/1 antiserum were examined and found not to be inhibited by any of the heterologous SOR-inhibitory antisera.
Strains of T-agglutination patterns 2, 9, 12, and 14 thus behaved similarly in that all SOR-positive strains examined from each of the four different T patterns produced a lipoproteinase common to other strains of the same T pattern, but anfigenically distinct from the lipoproteinases of strains of heterologous patterns. In the T-agglutination patterns to be considered next, the situation was more complex in that more than one class of strains could be distinguished within the T pattern by means of antigenically distinct lipoproteinase antigens. 
T-Agglutination Patterns Associated with
Heterologous T serotypes: All heterologous strains of groups I, II, and III (See Methods)
plus: M-negative, T 11 strains listed in Table HI footnote. :~ Strains whose SOR is inhibited by RLPA15 serum: RL1533, RL2415, RL2717, CV387, CV497A, CV677A.
§ Includes three strains whose SOR is inhibited by AN730 antiserum (See Table VIII ).
immunized rabbits. The results of SOR inhibition with one of these antisera are presented in Table VII ). strains whose SOR had been inhibited by RL2415 antiserum. The serum opacity reactions of M-typable strains in the 8/25/imp. 19 T pattern (types 8 and 25) tested were not inhibited by AN730 antiserum and the activities of strains of T pattern other than 8/25/imp. 19 were likewise not inhibited. The serum opacity reactions of the three strains inhibited by AN730 antiserum were not inhibited by the antiserum to the 8/25/imp. 19 strain RL2415 described above nor by antisera to strains of heterologous types.
Two antigenically different lipoproteinases were thus found among strains of T pattern 8/25/imp. 19. Since the majority of non-M-typable strains in this T pattern as well as M type 8 and 25 strains exhibited no SOR inhibition with either of the two antisera, it seems that several distinct strains as determined by lipoproteinase antigen are found in this complex T pattern.
Strains of T-Agglutination Pattern 11.--
A vaccine prepared from a non-M-typable strain of T-agglutination pattern 11 (CV238) produced acceptable antiserum in two of four immunized rabbits. As shown in Table IX , the serum opacity reactions of 8 of 18 strains of T pattern 11 were inhibited by CV238 antiserum, while the activities of all 19 strains of heterologous T pattern tested were not inhibited. The serum Table X ). § Strains whose SOR is inhibited by CV238 antiserum: 5763, AN124, AN441, CV238, CV595B, CV689, CV722, CV725A. Table IX ). opacity reactions of five strains which showed SOR inhibition by CV238 antiserum were not inhibited by heterologous SOR-inhibitory antisera, including the antiserum made from a M type 11 strain described below. In order to investigate further this T-agglutination pattern, a vaccine was prepared from the prototype type 11 M-producing strain (Tll/54/3). An acceptable antiserum was produced in one of three rabbits immunized. As shown in Table X , this antiserum only inhibited the SOR of the immunizing strain and did not inhibit the SOR of the 19 non-M-typable strains of T pattern 11 (eight of which were inhibited by CV238 antiserum) nor the SOR of strains of heterologous T-agglutination patterns. The SOR of strain Tll/54/3 was not inhibited by any of the other SOR-inhibitory antisera produced, including CV238 antiserum. Strains of T pattern 11 thus resemble those in M-negative, T 11 strains listed in Table H footnote. M-negative, T 12 strains: From Red Lake, strains Red Lake RL2802 and CV836B. All seven strains inhibited by T28/150A/3 antiserum (See Table XII ).
T pattern 8/25/imp. 19, in that at least two distinct kinds of strains as determined by specificity of lipoproteinase antigens exist within the T pattern.
Strains of T-Agglutination Pattern 28.--Strains wlth no 28 R antigen:
Two of three rabbits immunized produced suitable SOR-inhlbitory antiserum after immunization with a vaccine prepared from AN632, a non-M-typable strain of T pattern 28 whose acid extracts gave no precipitation with 28 R antiserum. As shown in Table XI, AN632 antiserum completely inhibited the SOR of all 18 strains in the T pattern which gave no precipitation with 28 R antiserum. AN632 antiserum partially inhibited the SOR of seven strains of the same T pattern which were shown to produce the 28 R antigen. AN632 antiserum did not inhibit the SOR of 64 strains of heterologous serotypes, including three which produced the 28 R antigen. The SOR of five of the strains whose SOR had been inhibited by AN632 antiserum was not inhibited when tested with the other SOR-inhibitory antisera produced, including that ihhibiting the SOR of a 28 R-producing strain (T28/ 150A/3) described below.
Strains with 28 R antigen: Results with SOR-inhibitory antiserum produced by immunization of rabbits with strain T28/150A/3, a type 28 strain producing the 28 R antigen are shown in Table 3=11 . The SOR of the 60 strains of heterologous serotypes was not inhibited by this antiserum, including the three strains of heterologous type which produced the 28 R antigen. T28/ 150A/3 antiserum completely inhibited the SOR of all 7 R-positive strains of Table (Table XI) . He~rologous T serotypes: All heterologous strains of groups I, II, and HI (See Methods).
The SOR of all 18 strains is inhibited by AN632 antiserum (See Table XI ).
T pattern 28 (whose SOR had been partially inhibited by AN632 antiserum), but did not inhibit the SOR of any of the 18 R-negative strains of T pattern 28 (whose SOR had been completely inhibited by AN632 antiserum). Five of the strains whose SOR was inhibited by T28/150A/3 antiserum were tested with the other inhibitory antisera produced. The SOR of these strains was unaffected by these antisera with the exception of A.N632 antiserum which resulted in partial inhibition. A one-way partial cross-reaction between lipoproteinase antigens was thus found in the two groups of strains (28 R-producing and non 28 R-producing) of T pattern 28. This cross-reaction may perhaps best be explained by a shared secondary antigenic determinant, although the alternative possibility that more than one lipoproteinase is produced by the two groups of strains and that strains of both groups share one of these antigens could not be disproved. The peculiar characteristics of lipoproteinase antigens render classic absorption techniques difficult in that antigen is extracted from the absorbing strain into the antiserum where it produces a serum opacity reaction during the absorption process and reduces the sensitivity of subsequent SOR-inhibition tests with the absorbed antisermn. Strains in the T-agglutination pattern 28 thus appear to produce two lipoproteinases which are antigenically related. A similar finding was apparent among strains in the T-agglutination pattern 5/27/44. Table VI footnote) .
Heterologous T Serotypes: All heterologous strains of groups I, II, and III (See Methods).
Strains whose SOR is completely inhibited by CV549 antiserum: RL3010B, RL3146, CV549, CV760A.
§ Strains whose SOR is partially inhibited by CV549 antiserum: 5937, 6134, RIA034, CV822B, AN586, CDC27.
Strains of T-Agglutination Pattern 5/27/44.--
The results of SOR inhibition by antiserum produced against a non-Mtypable strain of T pattern 5/27/44 (CV549) are shown in Table XIII . This antiserum was found to inhibit completely the SOR of four strains of T pattern 5/27/44 and partially the SOR of six other strains of this T pattern. Nine 5/27/44 strains showed no inhibition with CV549 antiserum nor did the 63 strains of heterologous T pattern tested. The serum opacity reactions of three strains of T pattern 5/27/44 whose SOR had been inhibited by CV549 antiserum were not inhibited when tested with heterologous SOR antisera.
Another antiserum was prepared by immunization with a second 5/27/44 strain (RL3034), a strain whose SOR had been partially inhibited by CV549 antiserum. As is shown in Table XIV , RL3034 antiserum inhibited the SOR of three of the 5/27/44 strains tested. The SOR of all of these strains had been partially inhibited by CV549 antiserum. The SOR of the remaining 5/27/44 strains (including four whose SOR had been completely inhibited by CV549 antiserum) and the SOR of strains of heterologous T patterns were not inhibited by RL3034 antiserum. The serum opacity reactions of the three strains whose activities were inhibited completely by RL3034 antisermn and partially by CV549 antiserum were not inhibited by the other SOR-inhibitory antisera. Table XIII) .
§ Includes the four strains from Table XIII whose SOR is completely inhibited by CV549 antiserum and the following two strains which are partially inhibited by CV349 antiserum:
5937, AN586.
DISCUSSION
Antisera prepared by the immunization of rabbits with crude Group A streptococcal cell wall-cell membrane fractions containing lipoproteinase activity have been shown to inhibit the serum opacity reaction (SOR) produced by the ~mmunizing strain. These antisera have been found also to inhibit the SOR of all or some strains homologous with respect to their T antigens, but they did not inhibit the SOR of strains heterologous with respect to T or M antigens. SOR inhibition by the antisera has been demonstrated using both ceU-associated and soluble enzyme. 12 antigenicaUy different streptococcal Hpoproteinases have been identified, and each of the enzymes showed some association with serotype, as determined by M and T antigens.
With respect to T antigens, a distinct lipoproteinase antigen was found only among strains in a single T-agglutination pattern. In some T patterns, i.e.
T patterns 2, 9, 12, and 14, all strains of a given T pattern produced immunologically indistinguishable lipoproteinase antigens. In other T patterns, i.e. T patterns 11, 28, 8/25/imp. 19, and 5/27/44, more than one class of strain could be differentiated by distinct lipoproteinase antigens within a T pattern.
With respect to M antigens, the majority of strains which produce a lipoproteinase are untypable or difficult to type by the precipitin method. We were only able to investigate strains of two M types, types 2 and 49, for specific lipoproteinase antigens. A single lipoproteinase antigen was invariably associated with each of the two M antigens. Each of the llpoproteinase antigens was found also in the non-M-typable strains of the corresponding T pattern 2 and T pattern 14, respectively.
It should be emphasized that the vaccines and enzyme preparations used in these experiments were relatively crude. Since antisera were raised against a cell wall-cell membrane fraction of streptococci, they undoubtedly contain antibodies to other streptococcal antigens besides lipoproteinase. Furthermore, desoxycholate extracts containing lipoproteinase also contain other antigens. A desoxycholate extract of strain CV238 when tested against antisera from rabbits ~rnmunized with that strain produced three distinct lines in gel diffusion. In view of the multiplicity of antigens contained in desoxycholate extracts and the multiplicity of antibodies in these antisera, it seems appropriate to compare some of the characteristics of lipoproteinase with those of other known streptococcal antigens with some specificity--the M, T, and R antigens-in order to examine the question of whether these antigens are identical with or distinct from streptococcal llpoproteinase.
Variation in SOR production between strains containing identical T antigens suggests that the T antigen and lipoproteinase antigen are distinct. Thus, in T-12 strains, the occurrence of a single T antigen in both variants of the same strain, one of which produces lipoproteinase and one of which fails to produce this enzyme, demonstrates that the T antigen and llpoproteinase antigen are separable by selection of variants (8) . As a second example, M type 4 strains produce lipoproteinase whereas types 24, 26, 29, and 46 strains do not (8) despite a serologically indistinguishable 4-24 T antigen in these strains (19) .
The 28 R antigen also appears to be distinct, both in serological specificity and strain distribution, from the lipoproteinase antigen. Antiserum inhibitory to the SOR of a type 2 strain which produced the 28 R antigen did not inhibit the SOR of a 28 R-producing type 28 or type 48 strain. This antiserum inhibited the SOR of strains of T-agglutination pattern 2 regardless of the presence or absence of the 28 R antigen in these strains. Furthermore, antiserum inhibiting the SOR of a 28 R-producing type 28 strain did not inhibit the SOR of a type 2 or a type 48 strain producing this antigen. Despite a common 28 R antigen in these three strains, they each produce an antigenically distinct lipopro-teinase. Furthermore, although a specific 28 R antiserum produced strong precipitation with extracts of these type 2, type 28, and type 48 strains, the same antiserum did not inhibit the SOR of any of these three strains.
Evidence of a difference in strain distribution between lipoproteinase and M antigens is derived from our experience (8) and that of others (6, 7) with strains of T-agglutination pattern 12. While M-typable type 12 strains do not produce lipoproteinase, naturally occurring M-negative strains and glossy variants of type 12 strains regularly produce lipoproteinase. This inverse relationship between lipoproteinase and type 12 M production among strains of this T-agglutination pattern suggests that the two antigens are distinct. As Apart from these differences in strain distribution and immunological specificity which distinguish the streptococcal lipoproteinase from previously well-established cellular antigens of Group A streptococci, observations from other directions suggest that the lipoproteinases have properties which are not uniformly shared by other streptococcal cell-associated antigens. In Table XV , certain characteristics of the M, T, and R antigens of Group A streptococci, as described by Lancefield and Dole (14) and Lancefield and Perlman (15, 16) , are compared with those for lipoproteinase, as described by Hill and Wannamaker (4) . It is well to consider that in the above studies the M, T, and R antigens were detected by precipitin tests whereas lipoproteinase was detected by its capacity to produce opalescence in serum. Lipoproteinase differs from the M antigen in its resistance to digestion with streptococcal proteinase, its lability to heat at pH 2, and its extractability by serum and desoxycholate solution. Lipoproteinase differs from the T antigens in its sensitivity to digestion with trypsin and pepsin and in its extractability by serum and desoxycholate. It differs from the 28 R antigen in its sensitivity to digestion with trypsin and in its extractability by serum. Moreover, the M, T, and R antigens are surface antigens which appear to be associated with or attached to the streptococcal cell wall, whereas available evidence suggests that the cell-bound lipoproteinase is associated predominantly with the cell membrane fraction (4) . Therefore, on the basis of lines of evidence of several different kinds, it seems likely that lipoproteinase is distinct from the M, T, and R antigens and that this enzyme represents a fourth Group A streptococcal antigen with rather remarkable serological specificity with respect to strain.
The production of immunologically distinct lipoproteinase antigens by strains of Group A streptococci currently difficult to type by the M precipitin method may provide a convenient tag for their more precise identification. Antiserum inhibiting lipoproteinase has already proved quite useful in our laboratory in the identification of presumed type 49 strains associated with acute glomerulonephritis, many of which have been difficult to type with type 49 M antiserum. In serotypes which produce lipoproteinase and for which reasonably acceptable M typing antisera are available, i.e. type 2 and type 9, a distinct lipoproteinase antigen was invariably found to be associated with a distinct M and T antigen. Whether the multiple distinct lipoproteinase antigens identified among strains with certain T patterns such as 11 and 8/25/imp. 19 will also be found to be associated with distinct M antigens will only be determined by further investigations of the M antigens in these strains. Thus, whereas the absence of lipoproteinase production was previously used as an indication of strains for which it might be profitable to explore the possibility of new M types (17) , the presence of lipoproteinases of different immunological specificity among strains in the same complex T pattern suggests a further useful method of identifying discrete strains within these patterns which could then be investigated for M antigens.
In view of the strain specificity of the streptococcal lipoproteinases, the antigenicity of these enzymes in humans as suggested by the reports of Krumwiede (2) and Rowen (5) deserves more intensive study. If further investigations confirm the antigenicity of lipoproteinase in humans, the enzyme may prove to be a convenient antigen for the determination of strain-specific antibodies to strains whose M antigens are currently difficult to identify.
SUMMARY
Investigation into the antigenicity of streptococcal lipoproteinase has revealed the existence of multiple, immunologicaUy distinct enzymes. Each lipoproteinase identified was found to be strain specific in that it was found only in strains of a particular T-agglutination pattern. In some T patterns, all streptococci of that T pattern which were examined shared a common lipoproteinase antigen. In other T patterns, strains which produced antigenically different lipoproteinases were identified. Evidence that the lipoproteinase antigen is distinct from other well-established cellular antigens of Group A streptococci has: been presented. The production of this strain-specific enzyme by strains currently difficult to type by the standard M precipitin method may facilitate more precise identification of these strains and a better assessment of their role in the pathogenesis of Group A streptococcal infections and their sequelae.
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